JWH-015

JWH-015
IUPAC ime
	(2-Metil-1-propil-1H-indol-3-il)-1-naftalenilmetanon
Pravni status
Pravni status	Legal;
Identifikatori
CAS broj	155471-08-2
ATC kod	none
PubChem	CID 4273754
Hemijski podaci
Formula	C23H21NO
Molarna masa	327,43 g/mol

JWH-015 je jedinjenje iz naftoilindolne familije koje deluje kao selektivni kanabinoidni agonist. Njegov afinitet za CB₂ receptor je 13,8 nM, dok je njegov afinitet za CB₁ 383 nM, tako da se skoro 28 puta jače vezuje za CB₂ nego CB₁.^[1] JWH-015 manifestuje slabu CB₁ aktivnost, i nije selektivan u istoj meri kao JWH-133.^[2] On ima imunomodulatorno dejstvo,^[3]^[4] i CB₂ agonisti potencijalno mogu da budu korisni u tretmanu bola i inflamacije.^[5]^[6]

Reference

^ Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Showalter VM, Abood ME, Martin BR. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB₁ and CB₂ receptor binding. Drug and Alcohol Dependence 2000; 60:133-140.
^ Marriott, KS; Huffman, JW (2008). „Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor”. Current Topics in Medicinal Chemistry. 8 (3): 187—204. PMID 18289088. doi:10.2174/156802608783498014.
^ Ghosh, S; Preet, A; Groopman, JE; Ganju, RK (2006). „Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes”. Molecular immunology. 43 (14): 2169—79. PMID 16503355. doi:10.1016/j.molimm.2006.01.005.
^ Montecucco, F; Burger, F; Mach, F; Steffens, S (2008). „CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways”. American journal of physiology. Heart and circulatory physiology. 294 (3): H1145—55. PMID 18178718. doi:10.1152/ajpheart.01328.2007.
^ Ehrhart, J; Obregon, D; Mori, T; Hou, H; Sun, N; Bai, Y; Klein, T; Fernandez, F; Tan, J (2005). „Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation”. Journal of neuroinflammation. 2: 29. PMC 1352348  . PMID 16343349. doi:10.1186/1742-2094-2-29.
^ Romero-Sandoval, A; Eisenach, JC (2007). „Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision”. Anesthesiology. 106 (4): 787—94. PMID 17413917. doi:10.1097/01.anes.0000264765.33673.6c.

Spoljašnje veze

[1] Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Showalter VM, Abood ME, Martin BR. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB₁ and CB₂ receptor binding. Drug and Alcohol Dependence 2000; 60:133-140.

[2] Marriott, KS; Huffman, JW (2008). „Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor”. Current Topics in Medicinal Chemistry. 8 (3): 187—204. PMID 18289088. doi:10.2174/156802608783498014.

[3] Ghosh, S; Preet, A; Groopman, JE; Ganju, RK (2006). „Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes”. Molecular immunology. 43 (14): 2169—79. PMID 16503355. doi:10.1016/j.molimm.2006.01.005.

[4] Montecucco, F; Burger, F; Mach, F; Steffens, S (2008). „CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways”. American journal of physiology. Heart and circulatory physiology. 294 (3): H1145—55. PMID 18178718. doi:10.1152/ajpheart.01328.2007.

[5] Ehrhart, J; Obregon, D; Mori, T; Hou, H; Sun, N; Bai, Y; Klein, T; Fernandez, F; Tan, J (2005). „Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation”. Journal of neuroinflammation. 2: 29. PMC 1352348  . PMID 16343349. doi:10.1186/1742-2094-2-29.

[6] Romero-Sandoval, A; Eisenach, JC (2007). „Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision”. Anesthesiology. 106 (4): 787—94. PMID 17413917. doi:10.1097/01.anes.0000264765.33673.6c.

[1]

[2]

[3]

[4]

[5]

[6]